West Pharmaceutical Services (NYSE:WST) Shares Gap Down – Here’s What Happened

West Pharmaceutical Services, Inc. (NYSE:WST) shares gapped down prior to trading on Tuesday . The stock had previously closed at $248.06, but opened at $240.39. West Pharmaceutical Services shares last traded at $235.9790, with a volume of 400,985 shares.

Analyst Upgrades and Downgrades

WST has been the subject of a number of analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $295.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. UBS Group reissued a “buy” rating and issued a $340.00 target price on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. Morgan Stanley started coverage on shares of West Pharmaceutical Services in a research report on Monday, December 1st. They issued an “equal weight” rating and a $285.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $315.00 price objective on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $314.56.

West Pharmaceutical Services Price Performance

The company has a current ratio of 3.02, a quick ratio of 2.34 and a debt-to-equity ratio of 0.06. The stock has a 50-day simple moving average of $251.55 and a 200 day simple moving average of $262.02. The stock has a market capitalization of $17.16 billion, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 2.51 and a beta of 1.17.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.21. The company had revenue of $805.00 million for the quarter, compared to the consensus estimate of $795.70 million. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. On average, equities research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be given a $0.22 dividend. The ex-dividend date is Wednesday, April 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio is presently 12.96%.

West Pharmaceutical Services announced that its board has initiated a share repurchase program on Tuesday, February 17th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 5.6% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of hedge funds have recently modified their holdings of WST. Flagship Harbor Advisors LLC boosted its position in West Pharmaceutical Services by 3.7% during the third quarter. Flagship Harbor Advisors LLC now owns 1,091 shares of the medical instruments supplier’s stock valued at $286,000 after purchasing an additional 39 shares during the last quarter. NewEdge Wealth LLC increased its position in West Pharmaceutical Services by 3.5% in the 3rd quarter. NewEdge Wealth LLC now owns 1,174 shares of the medical instruments supplier’s stock worth $333,000 after purchasing an additional 40 shares during the last quarter. Darwin Wealth Management LLC raised its stake in shares of West Pharmaceutical Services by 10.8% during the 4th quarter. Darwin Wealth Management LLC now owns 410 shares of the medical instruments supplier’s stock worth $113,000 after purchasing an additional 40 shares in the last quarter. RFG Advisory LLC raised its stake in shares of West Pharmaceutical Services by 2.2% during the 3rd quarter. RFG Advisory LLC now owns 2,233 shares of the medical instruments supplier’s stock worth $586,000 after purchasing an additional 47 shares in the last quarter. Finally, Aptus Capital Advisors LLC lifted its holdings in shares of West Pharmaceutical Services by 5.5% during the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after buying an additional 47 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.